Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amarnath Challapalli

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 10, 2012
Imaging apoptosis with positron emission tomography: 'bench to bedside' development of the caspase-3/7 specific radiotracer [(18)F]ICMT-11Quang-Dé Nguyen, Amarnath Challapalli, Graham Smith, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 10, 2026
Corrigendum to "Long-term outcomes from a multicentre study of HDR monotherapy with a single fraction of 19 Gy for localized prostate cancer" [Radiother. Oncol. 216 (2026) 111385]Wiwatchai Sittiwong, Anna Lydon, James Wylie, et al.
The British Journal of Radiology|May 11, 2024
Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligandsMitesh Naik, Sairah R Khan, Valerie Lewington, et al.
Biomarkers in Medicine|March 28, 2012
Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [(18)F] 3´-deoxy-3´-fluorothymidine PET: a pilot studyKaiyumars Contractor, Eric O Aboagye, Jimmy Jacob, et al.
Journal of Clinical Pathology|June 5, 2015
Exploiting altered patterns of choline kinase-alpha expression on human prostate tissue to prognosticate prostate cancerAmarnath Challapalli, Sebastian Trousil, Steve Hazell, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc|November 21, 2024
PSMA Radiotheranostics in Prostate Cancer: Principles, Practice, and Future ProspectsLaszlo K Szidonya, Tara D Barwick, Amarnath Challapalli, et al.
BJU International|April 27, 2026
A Delphi consensus for implementing genomic testing in unresectable or metastatic urothelial cancerSyed A Hussain, Amarnath Challapalli, Simran Gill, et al.
Frontiers in Immunology|July 29, 2024
Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab)Amarnath Challapalli, Grant Stewart, Heather Shaw, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 27, 2022
Eligibility for <sup>177</sup>Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of <sup>68</sup>Ga-PSMA-11 and <sup>99m</sup>Tc-MIP-1404 in Metastatic Castration-Resistant Prostate CancerGary J R Cook, Wai-Lup Wong, Bal Sanghera, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 5, 2014
Biodistribution and radiation dosimetry of deuterium-substituted 18F-fluoromethyl-[1, 2-2H4]choline in healthy volunteersAmarnath Challapalli, Rohini Sharma, William A Hallett, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|January 10, 2012
Imaging apoptosis with positron emission tomography: 'bench to bedside' development of the caspase-3/7 specific radiotracer [(18)F]ICMT-11Quang-Dé Nguyen, Amarnath Challapalli, Graham Smith, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 10, 2026
Corrigendum to "Long-term outcomes from a multicentre study of HDR monotherapy with a single fraction of 19 Gy for localized prostate cancer" [Radiother. Oncol. 216 (2026) 111385]Wiwatchai Sittiwong, Anna Lydon, James Wylie, et al.
The British Journal of Radiology|May 11, 2024
Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligandsMitesh Naik, Sairah R Khan, Valerie Lewington, et al.
Biomarkers in Medicine|March 28, 2012
Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [(18)F] 3´-deoxy-3´-fluorothymidine PET: a pilot studyKaiyumars Contractor, Eric O Aboagye, Jimmy Jacob, et al.
Journal of Clinical Pathology|June 5, 2015
Exploiting altered patterns of choline kinase-alpha expression on human prostate tissue to prognosticate prostate cancerAmarnath Challapalli, Sebastian Trousil, Steve Hazell, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc|November 21, 2024
PSMA Radiotheranostics in Prostate Cancer: Principles, Practice, and Future ProspectsLaszlo K Szidonya, Tara D Barwick, Amarnath Challapalli, et al.
BJU International|April 27, 2026
A Delphi consensus for implementing genomic testing in unresectable or metastatic urothelial cancerSyed A Hussain, Amarnath Challapalli, Simran Gill, et al.
Frontiers in Immunology|July 29, 2024
Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab)Amarnath Challapalli, Grant Stewart, Heather Shaw, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 27, 2022
Eligibility for <sup>177</sup>Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of <sup>68</sup>Ga-PSMA-11 and <sup>99m</sup>Tc-MIP-1404 in Metastatic Castration-Resistant Prostate CancerGary J R Cook, Wai-Lup Wong, Bal Sanghera, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 5, 2014
Biodistribution and radiation dosimetry of deuterium-substituted 18F-fluoromethyl-[1, 2-2H4]choline in healthy volunteersAmarnath Challapalli, Rohini Sharma, William A Hallett, et al.
Pageof 4